<DOC>
	<DOC>NCT01408342</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.</brief_summary>
	<brief_title>Alemtuzumab and Rituximab in Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia, Aplastic</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients with aplastic anemia diagnosis Patients with prior treatment with monoclonal antibodies and/or antithymocyte globulin. Patients with a diagnosis or history of HIV/AIDS, Hepatitis B, Hepatitis C, Cytomegalovirus. Patients who do not agree to sign a Letter of Informed Consent.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Alemtuzumab</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Aplastic anemia</keyword>
	<keyword>cyclosporine</keyword>
</DOC>